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Abstract
Intranasal delivery provides a practical, non-invasive method of bypassing the blood-brain barrier
(BBB) to deliver therapeutic agents to the brain and spinal cord. This technology allows drugs that
do not cross the BBB to be delivered to the central nervous system within minutes. It also directly
delivers drugs that do cross the BBB to the brain, eliminating the need for systemic administration
and its potential side effects. This is possible because of the unique connections that the olfactory
and trigeminal nerves provide between the brain and external environment. Intranasal delivery
does not necessarily require any modification to therapeutic agents. A wide variety of therapeutics,
including both small molecules and macromolecules, can be targeted to the olfactory system and
connected memory areas affected by Alzheimer's disease. Using the intranasal delivery system,
researchers have reversed neurodegeneration and rescued memory in a transgenic mouse model
of Alzheimer's disease. Intranasal insulin-like growth factor-I, deferoxamine, and erythropoietin
have been shown to protect the brain against stroke in animal models. Intranasal delivery has been
used to target the neuroprotective peptide NAP to the brain to treat neurodegeneration.
Intranasal fibroblast growth factor-2 and epidermal growth factor have been shown to stimulate
neurogenesis in adult animals. Intranasal insulin improves memory, attention, and functioning in
patients with Alzheimer's disease or mild cognitive impairment, and even improves memory and
mood in normal adult humans. This new method of delivery can revolutionize the treatment of
Alzheimer's disease, stroke, and other brain disorders.
Introduction
The use of intranasal (IN) administration to target thera-
peutics to the central nervous system (CNS) has many
benefits in the treatment of neurologic disorders. The
blood-brain barrier (BBB) restricts the use of numerous
therapeutic agents that have been developed to treat
memory loss and neurodegeneration because it limits
CNS penetration, depending on drug size or charge.
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Although invasive methods of administration (for
instance intracerebroventricular) have been used to over-
come the BBB, these methods are not practical for use in
humans for several reasons, including convenience,
safety, and cost. Direct delivery of therapeutics from the
nasal cavity into the CNS (IN delivery) bypasses the BBB
and provides an alternative to invasive methods of drug
administration [1,2]. Noninvasive IN delivery targets ther-
apeutics to the CNS, reducing systemic exposure and side
effects; this can be advantageous for delivery of many CNS
therapeutics, including those that can cross the BBB upon
systemic administration. CNS therapeutics do not neces-
sarily need to be modified for IN delivery, and delivery of
therapeutics to the CNS is rapid, occurring within min-
utes. The IN delivery method was first developed by Frey
in 1989 [3] for targeting neurotrophic factors (for exam-
ple, nerve growth factor [NGF] and fibroblast growth fac-
tor-2) to the CNS.
Olfactory and trigeminal pathways
Intranasally administered therapeutics reach the CNS via
the olfactory and trigeminal neural pathways. Both the
olfactory and trigeminal nerves innervate the nasal cavity,
providing a direct connection with the CNS. Direct deliv-
ery of therapeutics from the nose to the brain was initially
attributed to the olfactory pathway [3-6]. More recently,
the contribution made by the trigeminal pathway to IN
delivery to the CNS has also been recognized, especially to
caudal brain regions and the spinal cord [7,8]. Extracellu-
lar delivery, rather than axonal transport, is strongly indi-
cated by the short time frame (≤ 10 minutes) observed for
IN therapeutics to reach the brain from the nasal mucosa.
Possible mechanisms of transport may involve bulk flow
and diffusion within perineuronal channels, perivascular
spaces, or lymphatic channels directly connected to brain
tissue or cerebrospinal fluid [9].
Intranasal delivery targets therapeutics to the 
central nervous system
IN delivery has been used to target a wide variety of ther-
apeutics to the CNS. For example, the following classes of
therapeutics have successfully been intranasally delivered
to the CNS: neurotrophins (NGF [5] and insulin-like
growth factor [IGF]-1 [7]); neuropeptides (hypocretin-1
[10] and exendin [11]); cytokines (interferon β-1b [8] and
erythropoietin [12]); polynucleotides (DNA plasmids
[13] and genes [14]); and small molecules (chemothera-
peutics [15] and carbamazepine [16]). IN delivery works
best for potent therapeutics that are active in the nanomo-
lar range [1]. Even therapeutics that are substrates for the
P-glycoprotein efflux transporter, which is known to oper-
ate in the nasal epithelium, have been reported to reach
the CNS in effective concentrations [17].
Intranasal neurotrophins for the treatment of 
neurodegeneration
Although the ability of neurotrophins to protect and pro-
mote the growth of new neurons makes them desirable
candidates for the treatment of neurodegenerative disease,
the inability of neurotrophins to cross the BBB efficiently,
and the impracticality of invasive injection methods, have
prevented their use. Growing evidence suggests that IN
administration of neurotrophins provides a noninvasive
way to target neurotrophins to the CNS to treat neurode-
generation. In a mouse model of Alzheimer's disease, IN
administered NGF both reduced neurodegeneration and
improved performance in memory tasks [18,19]. In a rat
model of stroke, IN IGF-I reduced brain damage and neu-
rologic deficits [20]. In addition, cerebral neurogenesis
was induced in the subventricular zone of adult mice after
IN administration of FGF-2 [21]. IN activity dependent
neurotrophic factor, as well as its active peptide fragment
NAP, have been shown to reduce neurodegeneration, tau
pathology, amyloid accumulation, and memory loss in
mouse models of Alzheimer's disease [22-25]. IN NAP is
now being tested in phase II clinical trials as a potential
treatment for Alzheimer's disease and mild cognitive
impairment.
Memory is improved by intranasal insulin treatment
IN insulin improves memory in normal adults and
patients with Alzheimer's disease without altering blood
glucose. Energy metabolism in the CNS is dependent
upon glucose uptake and is regulated by insulin in key
brain regions. It has long been known that glucose uptake
and utilization are deficient in patients with Alzheimer's
disease [26]. Recently, the gene expression levels of insu-
lin, IGF-1, and their receptors were shown to be markedly
reduced in the brains of patients with Alzheimer's disease
[27]. Consequently, ability to deliver insulin to the CNS
without altering blood glucose could provide an effective
means to improve glucose uptake and utilization, and
reduce cognitive deficits in patients with memory disor-
ders.
Using the IN delivery method to target insulin to the CNS
originally developed by Frey [28], Born and coworkers
[29] demonstrated that cerebrospinal fluid insulin levels
significantly increased after treatment of normal adults
with insulin, with no change in blood levels of insulin. In
normal adults, IN treatment with insulin for 8 weeks
improved memory (delayed recall of words) and mood at
doses that did not alter blood levels of insulin or glucose
[30]. In addition, IN administration of a rapidly acting
form of insulin that forms hexamers and is more rapidly
absorbed, insulin aspart, improved memory in normal
adults significantly more than did regular insulin [31]. In
Alzheimer's patients, a single IN treatment acutely
improved verbal memory (total story recall and total wordBMC Neuroscience 2008, 9(Suppl 3):S5 http://www.biomedcentral.com/1471-2202/9/S3/S5
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list recall) at doses that did not alter blood levels of insu-
lin or glucose [32]. The benefit of IN insulin treatment
was seen primarily for Alzheimer's patients without the
apolipoprotein E ε4 allele. Longer treatment with IN insu-
lin (21 days) enhanced memory, attention, and function-
ing compared with placebo in patients with either early
stage Alzheimer's disease or mild cognitive impairment
[33,34].
Conclusion
IN delivery is a noninvasive method that bypasses the BBB
and targets drugs to the CNS, reducing systemic exposure
and side effects. This novel method has already been used
successfully to improve memory in both normal adults
and patients with Alzheimer's disease. IN delivery could
revolutionize the way we treat Alzheimer's disease and
other neurodegenerative disorders.
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